Ignite Creation Date:
2024-05-06 @ 12:51 PM
Last Modification Date:
2024-10-26 @ 1:05 PM
Study NCT ID:
NCT03861793
Status:
COMPLETED
Last Update Posted:
2024-03-05
First Post:
2019-02-25
Brief Title:
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 Nemvaleukin Alfa as a Single Agent and in Combination With Anti-PD-1 Antibody Pembrolizumab in Subjects With Select Advanced or Metastatic Solid Tumors ARTISTRY-2
Sponsor:
Mural Oncology Inc
Organization:
Mural Oncology Inc
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Advanced Solid Tumors |
Keywords:
| Name | View |
|---|---|
| adenocarcinoma | View |
| Alkermes | View |
| IL-2 | View |
| Interleukin-2 | View |
| Oncology | View |
| Immuno-oncology | View |
| Cytokine | View |
| ALKS 4230 | View |
| Pembrolizumab | View |
| Keytruda | View |
| PD-L1 | View |
| Solid tumors | View |
| Immunotherapy | View |
| nemvaleukin alfa | View |
| ovarian | View |
| Head and Neck | View |
| NSCLC | View |
| Non small cell lung cancer | View |
| lung cancer | View |
| Gastric | View |
| Gastric Cancer | View |
| Gastroesophageal Cancer | View |
| Gastroesophageal junction GEJ adenocarcinoma | View |
| GEJ Cancer | View |